Impact of COVID 19 on Guillain-Barré Syndrome in India
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: G610- Guillain-Barre syndrome
- Registration Number
- CTRI/2020/11/029143
- Lead Sponsor
- AIIMS New delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Diagnosis of GBS confirmed by diagnostic criteria for GBS of the National Institute of Neurological Disorders and Stroke (NINDS) or one of the variants of GBS, including the MFS and overlap syndromes
2. Hospital admission within 4 - weeks of the onset of weakness (or other symptoms attributed to GBS.
Exclusion Criteria
1. Subacute Inflammatory demyelinating neuropathy (SIDP)
2. Toxic neuropathies
3. Vasculitic neuropathies
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with GBS admitted during COVID pandemic compared to similar period in the previous yearTimepoint: 7 months
- Secondary Outcome Measures
Name Time Method Demographic characteristics of GBS patientsTimepoint: 7 months;Proportion of GBS patients requiring invasive ventilationTimepoint: 7 months;Proportion of GBS patients who received IVIGTimepoint: 7 months;Proportion of GBS patients who received Plasma exchangeTimepoint: 7 months